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S U M M A R Y
Introduction: The role of damage-associated molecular pattern HMGB1 signalling in a murine BALB/c
model of severe respiratory melioidosis (Burkholderia pseudomallei infection) was explored in this study.
Methods: Time course experiments were performed.
Results: It was established that HMGB1 was released in concert with increasing weight of organs and
increasing concentration of liver enzymes in the blood a short time after cytokine release. Differences in
the cytokine response between organs were observed, where the lungs contained higher concentrations
of chemokines and interleukin 17, while the spleen produced more interferon-gamma, which is essential
in the host defence against B. pseudomallei. This is evidence as to why the disease is seemingly more
severe in the respiratory form. The effect of depleting HMGB1 using an antibody was also evaluated. It
was found that this treatment signiﬁcantly reduced bacterial load in the liver, spleen, and, to a greater
degree, in the lungs. Cytokine quantiﬁcation indicated that this reduction in bacterial load is likely due to
the treatment reducing the release of a variety of pro-inﬂammatory cytokines.
Conclusion: It is concluded that anti-HMGB1 treatment would be effective alongside other therapeutics,
where it would reduce the characteristic over-inﬂammation associated with late stage infection.
Crown Copyright  2015 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The Gram-negative bacterial species Burkholderia pseudomallei
is the causative agent of melioidosis. Melioidosis is one of the
leading causes of septicaemia in certain Southeast Asian coun-
tries.1 From the environment, B. pseudomallei can enter the host via
different routes, and the most common routes are believed to be
through the drinking of contaminated water and through cuts and
abrasions of the skin.1 It is also recognized that B. pseudomallei can
cause particularly unpleasant primary and secondary pneumonia,2
and this contributes to the argument that B. pseudomallei
represents a credible bio-threat agent.3 Melioidosis can be
modelled in the laboratory in mice.4–7 One complication of
melioidosis is that B. pseudomallei has intrinsic tolerance to a
variety of antibiotic drugs, making treatment complex and§  Crown Copyright 2015, published with permission from the Defence Science
and Technology Laboratory, on behalf of the controller of HMSO.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).difﬁcult,8 and this indicates the requirement for novel therapeutics
to treat the disease.
When considering the immune response to B. pseudomallei,
much murine work has been performed to understand the
infectious process, and some of this has been supported by clinical
studies. The inability of the immune response to control infection
in two speciﬁc ways results in sepsis and death. Firstly, it is known
that neutrophils are important in limiting the morbidity of the
disease. Murine neutrophils can be observed taking up the bacteria
in in vivo models of respiratory disease,9 mice that have had
neutrophils ablated are hyper-sensitive to infection by B.
pseudomallei,10 and human melioidosis is often linked with
disorders that impair neutrophil function.11 However, neutrophils
are not a ubiquitously beneﬁcial cell and it has been demonstrated
that the activity of neutrophils can contribute to the severe damage
associated with disease.12 Interferon-gamma (IFN-g) signalling is
also known to be essential in the control of B. pseudomallei. A
plethora of work has been done to understand the cytokine
response,13–19 which has resulted in an understanding that
B. pseudomallei seems to prevent pyroptosis, therefore reducing
IFN-g, interleukin (IL)-12, and IL-18 secretion; this results inSociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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sepsis.20
The role of damage-associated molecular pattern (DAMP)
signalling is diverse and has started to be elucidated.21 Speciﬁcally,
there is a growing body of work aimed at understanding the role of
high-mobility group B protein 1 (HMGB1) signalling in a variety of
inﬂammatory conditions.22 Until recently, little was known about
whether DAMP signalling may contribute to the disease process of
melioidosis. Charoensup et al. ﬁrst established that increased
levels of HMGB1 in human melioidosis patients correlated with a
poor prognosis and secondly explored the therapeutic potential of
targeting HMGB1 in a murine model of melioidosis.23 They found
that knockdown of HMGB1 had no effect on survival independent
of other treatments, but had a modest effect when administered in
combination with ceftazidime.
Our study group also has an interest in HMGB1 as a target to treat
infectious disease; in a previous study, it was found that HMGB1 had
therapeutic beneﬁt when used against infection by the bacterium
Francisella tularensis.24 In the present study, the therapeutic
potential of anti-HMGB1 was investigated in a mouse model of
melioidosis in which BALB/c mice were infected by aerosol route.
2. Materials and methods
2.1. Mice
Six to eight-week-old female BALB/c mice (Charles River, UK)
were transferred to a high-containment class III rigid isolator,
where they were assigned randomly to groups and given unlimited
access to food and water. Mice were challenged with B.
pseudomallei strain K96243 by aerosol, as described previously,
using a Henderson-type apparatus25 and a Collison nebulizer.26Figure 1. Organ bacterial load, organ weight, blood glucose, blood liver enzyme, and HMG
K96243 by the aerosol route. Data from two experiments are shown. Groups of ﬁve mice w
the two experiments were 75 and 217 CFU. Values for each mouse are shown with symb
liver, spleen, and whole mouse). Panel B shows the bacterial load in CFU/organ (lung, li
concentrations in the blood serum (alanine aminotransferase (ALT) and aspartate amino
markers are indicative of Bonferroni post-test comparisons to naı¨ve mice (*p < 0.05, **Bacteria were grown in Luria broth at 37 8C on a rotary platform.
Mice were checked twice daily and scored for clinical signs. Mice
were culled at predetermined humane endpoints. Survival times
were recorded for some mice, and others were culled for analysis of
tissues at different time points. All procedures and housing were in
accordance with the United Kingdom Animal (Scientiﬁc Proce-
dures) Act (1986). Shinotest anti-HMGB1 and isotype control IgY
were obtained from Oxford Biosystems Cadama (UK). A 600-mg
dose of either antibody was administered by intraperitoneal route
at 24 h and 48 h post-infection to the appropriate mice.
2.2. Post-mortem analysis
Whole blood was micro-centrifuged at 7000 rpm for 20 min,
and the serum was removed and stored at 80 8C. Serum HMGB1
was measured with an ELISA kit (Shinotest, supplied through
Oxford Biosystems Cadama, UK) in accordance with the manufac-
turer’s instructions. Serum was also tested using a ‘dry-slide’
technology biochemistry analyser (VetTest; IDEXX Laboratories) in
accordance with the manufacturer’s instructions.
The lung, liver, spleen, and blood were all processed at less than
1 h post-mortem. All organs were weighed and collected in 2 ml
phosphate buffered saline (PBS) and then disrupted through a
40-mm cell sieve, and the resulting homogenate was collected.
Subsequently, 100-ml aliquots of the cell suspension were used for
enumeration of bacteria on agar following serial dilution in PBS
and plating out on Luria agar. For cytokine analysis, 200-ml
aliquots of cell suspension were centrifuged for 5 min at 2000 rpm.
Supernatants were removed for cytokine analysis and stored at
80 8C. The levels of cytokine were measured via 23-plex
murine Luminex array (Bio-Rad), used in accordence with the
manufacturer’s instructions. In addition, a magnetic plate washerB1 in BALB/c mice at time points post infection with Burkholderia pseudomallei strain
ere culled before, or 24 h, 48 h or 60 h post infection. Estimated challenge doses for
ols and the median values are included as lines. Panel A shows organ weights (lung,
ver, and spleen). Panel C shows blood serum glucose. Panel D shows liver enzyme
transferase (AST)). Panel E shows blood serum HMGB1 concentrations. Signiﬁcance
p < 0.01, ***p < 0.001).
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ﬁxed using 4% paraformaldehyde in PBS for at least 24 h at 4 8C.
2.3. Statistical analysis
Graphs were constructed using the program GraphPad PRISM v.
6.0. All statistical analyses were performed using IBM SPSS v.
21.0 software. For analysis, all data (with the exception of the
organ weight data) were transformed by the logarithm of 10 to
better ﬁt the normal distribution. Data were analysed by general
linear model (GLM), and validity of the test was established by
Levene’s tests for unequal variance. Data points were taken from
multiple experiments and for this reason the experiment with
which each data point was taken is included in the GLM as an
additional factor. Individual comparisons between groups were
performed by Bonferroni post-tests.
3. Results
3.1. HMGB1 release occurs with organ damage in a murine model of
melioidosis
To study the pathogenesis of the infection in mice, two time
course experiments were performed, in which groups of ﬁve miceFigure 2. Cytokine release at time points post infection withBurkholderia pseudomallei strain 
were culled before, or 24 h, 48 h or 60 h post infection. Estimated challenge doses for the
concentration across all 10 mice per time point. The error bars are indicative of the 95% con
variation associated with experimental run had been removed using general linear mode
whether cytokine levels are changing betweengroups (*p < 0.05, **p < 0.01, ***p < 0.001). Pa
load, at each time point post infection (24, 48, and 60 h). Each data point is the mean of the were culled prior to infection (as a baseline), and at 24, 48, and 60 h
post infection with estimated doses of 75 and 217 colony-forming
units (CFU) delivered by aerosol route.
As the disease progressed, bacterial numbers increased in all
organs (p < 0.001, using a multivariate GLM; Figure 1A). At the
same time as the increase in bacterial load, signiﬁcant increases in
organ mass of the lung and spleen were observed (both p < 0.001,
using a multivariate GLM) and a signiﬁcant reduction in overall
mouse weight (p < 0.001, using a GLM) (Figure 1B). Moreover
organ weights increased signiﬁcantly when compared to naı¨ve
mice from the 48 h time point in the lung and 60 h time point in the
spleen (p < 0.001, using Bonferroni post-tests). Mouse total body
weight was signiﬁcantly lower at 60 h post infection when
compared to the control mice (p < 0.001, using Bonferroni post-
tests). Serum was analysed using a blood chemistry analysis
system. During infection, blood glucose decreased signiﬁcantly
(p < 0.001, using GLM, Figure 1C) to levels below the level of naı¨ve
mice at 48 h and 60 h (p < 0.001, in both cases using Bonferroni
post-tests). Signiﬁcant increases in the concentration of the liver
enzymes alanine aminotransferase and aspartate aminotransfer-
ase were also observed as the infection progressed (both p < 0.001,
using a multivariate GLM; Figure 1D). The level of these enzymes
had risen signiﬁcantly over background at 48 h and 60 h (p < 0.05,
in all four cases, using Bonferroni post-tests). Finally, HMGB1K96243 by the aerosol route. Data from two experiments are shown. Groups ofﬁve mice
 two experiments were 75 and 217 CFU. Panel A shows the mean cytokine/bacterial
ﬁdence intervals. The error bars are indicative of the 95% conﬁdence intervals after the
l (GLM). Signiﬁcance markers are indicative of multivariate GLM analysis to indicate
nel B shows the fold inductionofcytokine (compared to naı¨ve mice) relative to bacterial
10 replicates. The circles are the lung, the squares the liver, and the crosses the spleen.
Fig. . (Continued ).
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infection (p < 0.001 using GLM; Figure 1E), rising by several fold
after infection to levels signiﬁcantly higher than background at
48 h and 60 h (p < 0.05, for both cases, using Bonferroni post-
tests).
Luminex technology was used explore the cytokine response
within the mouse organs at each time point post infection
(representative results are shown in Figure 2A). Furthermore,
these data were analysed by multivariate GLM to show that the
level of different cytokines changed as the infection developed in
different organs. It was observed that some cytokine concentra-
tions were signiﬁcantly altered in one organ, but not in another.
For example, signiﬁcant changes in IFN-g expression were
observed in the liver and spleen (p < 0.001, using GLM), but notin the lung (p > 0.10, using GLM). In order to better understand the
differences in cytokine dynamics between organs, the induction
of cytokine (relative to baseline, naı¨ve mice) was plotted against
the bacterial load at all time points (Figure 2B). Here the bacterial
load is regarded as a crude measure of antigen present to show
how the different organs respond relative to each other. For IL-1a,
IL-6, IL-12p40, IL-12p70, IL-17, granulocyte/monocyte colony
stimulating factor (GM-CSF) chemokine, C–C motif ligand (CCL)4,
and tumour necrosis factor alpha (TNF-a), induction of these
cytokines relative to bacterial load was very similar between
organs. This was not true of IL-1b, IL-4, IL-10, IFN-g, chemokine,
C–X–C motif ligand (CXCL)1, CCL2, CCL3, and CCL5. Seemingly,
and relative to the infectious load, release of these cytokines is
reduced in the lung.
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cytokine proﬁle during a B. pseudomallei infection in mice
The increase in the DAMP signal HMGB1 observed in mice post
infection with B. pseudomallei opened up the possibility that
reduction of this inﬂammatory signal may have a beneﬁcial effect.
Two experiments were performed in which mice were infected
with B. pseudomallei strain K96423 by the aerosol route (receiving
188 CFU/mouse in one experiment and 246 CFU in the other).
Mice were treated with either anti-HMGB1 (n = 20, 10 from each
experiment) or with an isotype control (n = 20, 10 from each
experiment). Survival was monitored and no signiﬁcant difference
in time to death was observed (p = 0.119, using a log-rank test
stratiﬁed by experiment; Figure 3A). Additional mice (n = 15, ﬁve
receiving 188 CFU/mouse, ﬁve receiving 246 CFU/mouse, and ﬁve
receiving 104 CFU/mouse) were culled at 48 h post infection in
order to assess the progression of disease.
It was found that anti-HMGB1 treatment reduced bacterial load
across all three organs investigated (p < 0.001, using a repeated
measures GLM; Figure 3B); this was most evident in the lung
(p < 0.001, using GLM), but was also seen in the liver and spleen
(p < 0.05, using GLM). No signiﬁcant difference in organ weights
was observed (data not shown). To further investigate how the
anti-HMGB1 treatment may have brought about the change in
bacterial load, Luminex analysis was performed to measureFigure 3. Survival and 48-h post infection organ bacterial load of BALB/c mice
treated with either anti-HMGB1 or an isotype and infected with Burkholderia
pseudomallei strain K96243 by the aerosol route. Chicken anti-HMGB1 (600 mg) or
IgY isotype (600 mg) was delivered at 24 h and at 48 h post infection by the
intraperitoneal route. Survival is shown with a Kaplan–Meier plot in panel A, and
includes survival data for 20 mice in each group combining two independent
experiments where mice received an estimated dose of either 188 CFU (n = 10) or
246 CFU (n = 10). Bacterial load is shown in panel B, and three independent
experiments (n = 5/group in each experiment) were performed; the median
bacterial concentration across all mice (line) and the count for each mouse
(symbols) is shown. The estimated doses were 188, 246, and 104 CFU per mouse for
each experiment.changes in cytokine release in different organs (Figure 4). Through
analysis by multivariate GLM, signiﬁcant reductions in several
cytokines in the HMGB1 treated group were noted when compared
to the isotype control treated group. These reductions included the
following: in the lung IL-4 (p < 0.001), IL-6 (p < 0.05), IL-12p70
(p < 0.01), CXCL1 (p < 0.01), CCL3 (p < 0.05), and TNF-a (p < 0.05);
in the liver IL-1b (p < 0.05) and IL-12p40 (p < 0.05); in the spleen
TNF-a (p < 0.01).
4. Discussion
Time course experiments were performed in the BALB/c mouse
model to identify whether HMGB1 is released during respiratory
disease caused by B. pseudomallei. In order to monitor and quantify
the growth of bacteria and their effects, three organs were selected
(lung, spleen, and liver) and bacterial growth, pathology (organ
weight), and cytokine release were investigated. The bacterial
growth that was observed occurred more rapidly than in some
previously published infection studies;27–29 however, these data
are very similar to those of a recent study that used a similar and
more substantial inoculum of bacteria30 and to previous work
within our institute.9,31
The total weight of the mice dropped during infection and this
has been observed elsewhere;28 however this is the ﬁrst time that
organ weight in a murine B. pseudomallei infection model has been
reported. Both the lung (from 48 h) and spleen (from 60 h) showed
signiﬁcantly increased weights, in the face of total weight loss. As
an infection effect, this might be a consequence of immune
inﬁltrate.9,27 The reason why the spleen showed a delayed weight
increase is likely because it takes between 3 and 10 h for bacteria to
colonize the spleen from the lung.9 No signiﬁcant increase in liver
mass was observed during the course of infection. This is likely due
to a number of factors, but is probably due to the liver having a
substantially lower density of infection (similar numbers of
bacteria per gram were observed between lung, liver, and spleen;
however the liver is approximately 10-fold larger). The observed
increase in liver enzymes in the blood and reduction in blood
glucose might be indicative of liver damage and this warrants
further investigation.
It was observed that the concentrations of many cytokines in
the lung, liver, and spleen increased with the progression of
disease. Many of the cytokines titrated in this study had been
measured in previous studies and the present data are broadly
consistent with those of previous studies.9,32,33 The present data
go beyond these datasets and demonstrate that some cytokines
are more prevalent within different organs. Speciﬁcally, it appears
that, relative to bacterial load, the lung releases less IL-1b, IL-4, IL-
10, IFN-g, CXCL1, CCL2, CCL3, and CCL5. A previous study by Tan
et al. showed that cytokine release is different in the lung and
spleen at a single time point post infection.32 In this study by Tan
et al., similar differences in cytokine release were observed: more
TNF-a and CCL2 were released in the lung, while, adjusted for the
lower infectious load, the spleen produced more IFN-g. It is well-
known that the lung is an organ rich in anti-inﬂammatory signals
and this is assumed to prevent unnecessary inﬂammation against
non-self-antigens, associated with the constant air exchange;34
this might be the cause of the cytokine deﬁcit within the lung. It is
unclear whether interventions that address this cytokine deﬁcit
would be of beneﬁt. It is also feasible that we are observing the
maximal output of IL-1b, IL-4, IL-10, IFN-g, CXCL1, CCL2, CCL3,
and CCL5 per gram of tissue and that the seeming reduction of
cytokine release in the lung is simply a function of the greater
infectious load being unable to further increase cytokine
concentrations.
To our knowledge this is the ﬁrst report to publish the dynamics
of IL-17 release in a murine model of melioidosis. The IL-17
Figure 4. Cytokine release 48 h post infection in BALB/c mice organs treated with either anti-HMGB1 or isotype and infected with Burkholderia pseudomallei strain K96243 by
the aerosol route. Anti-HMGB1 (600 mg) or IgY isotype (600 mg) was delivered at 24 h and at 48 h post infection by the intraperitoneal route. Three independent experiments
(n = 5/group in each experiment) were performed; the mean cytokine/bacterial concentration across all mice is shown. The estimated doses were 188, 246, and 104 CFU per
mouse for each experiment. The error bars are indicative of the 95% conﬁdence intervals. When the variation associated with experimental run had been removed using
general linear model (GLM). The signiﬁcance markers are indicative of GLM main effect estimations, where the Bonferroni correction has been applied. Filled symbols are the
anti-HMGB1 treated groups and open symbols are the isotype control treated group.
T.R. Laws et al. / International Journal of Infectious Diseases 40 (2015) 1–86concentration has previously been measured in a time course
study in blood, and no time dynamics were observed.28 In humans,
it was reported that patients with diabetes (a major risk factor in
melioidosis) had reduced IL-17 production in response to
Burkholderia antigens.35 IL-17 release in this mouse model of
infection was low.
In agreement with Charoensup et al., it was shown that
concentrations of the DAMP HMGB1 increased after infection in
mice in the present study.23 This is likely due to the infection and
the immunopathological organ damage associated with the
infection, causing the release of DAMPs. This has led us to thesame conclusion as Charoensup and colleagues: that experimental
interference with HMGB1 signalling may inﬂuence the course of
disease. To investigate this, an HMGB1 speciﬁc antibody was used
to reduce HMGB1 signalling in vivo and infection studies were
performed comparing these mice to mice treated with an isotype
control. This antibody intervention has been used previously in our
laboratory in a different infection model.24 The analysis of mouse
survival without antibiotic treatment resulted in the same
conclusions being drawn as in the similar experiment performed
previously:23 that HMGB1 depletion as a monotherapy does not
signiﬁcantly impact on the progression of melioidosis. Despite the
T.R. Laws et al. / International Journal of Infectious Diseases 40 (2015) 1–8 7lack of effect, the possibility exists that anti-HMGB1 treatment
may have had a limited effect, masked by the acute nature of B.
pseudomallei infection, in this model. For this reason, controlled
culls were performed at 48 h post infection and a variety of
parameters were measured. In these experiments, inhibition of
HMGB1 signalling reduced bacterial burden within all three organs
and most signiﬁcantly within the lung. This apparent disparity in
results, where anti-HMGB1 treatment reduced bacterial load but
did not enhance survival, is likely a consequence of statistical
power. On a continuous scale, bacterial load can be analysed with
powerful parametric techniques, whereas differences in survival
data are limited to the quanta of the time intervals over which
animals are observed (twice daily in this study). These quanta can
be increased through tempering the infection with antibiotics,
allowing more time points for differences in survival to manifest,
and this was done with success in the previous study.23
In addition it was found that anti-HMGB1 treatment inﬂuenced
cytokine concentration within the organs. Speciﬁcally the greatest
effect of cytokine concentration was within the lung, where the
anti-HMGB1 treatment signiﬁcantly reduced levels of IL-4, IL-6, IL-
10, IL12-p70, GM-CSF, CXCL1, CCL3, and TNF-a; however reductions
in IL-1b and IL-12p40 were observed in the spleen and TNF-a in the
liver. The present analysis did not exclude the possibility that any
other cytokines are reduced by anti-HMGB1 infection; the
experimental design was not sufﬁciently powerful to determine
that cytokine levels were unaffected by treatment. Critically, these
data do show that some pro-inﬂammatory cytokines are lowered by
the treatment, and with the reduction in bacterial load in mind, this
is consistent with our current understanding of the role of the
immune response in melioidosis. Pro-inﬂammatory signals may not
always be beneﬁcial20 and even have the potential to be
detrimental.36 In short, it is believed that the anti-HMGB1
treatment tempered the immune response and thus reduced
immune dysregulation, therefore allowing a better, more ‘managed’
immune response to attempt to control the infection. By this
reasoning it might be considered that HMGB1 induced inﬂamma-
tion is additive and detrimental during acute infections. This theory
is supported by the TNF-a levels, which were reduced in both the
liver and lung suggesting that the overall immune response has
been tempered. Previously, TNF-a was found to contribute to host
protection and when it was ablated, mice were found to be
hypersensitive to B. pseudomallei infection.19 The present data are
different in that, rather than the ablation of TNF-a in its entirety, the
presence of this cytokine was reduced and it is this that we
hypothesize contributes to a better anti-microbial response.
In our previous work with the bacterial pathogen F. tularensis,
HMGB1 reduction increased IFN-g release. It is unfortunate that
during B. pseudomallei infection HMGB1 reduction did not increase
IFN-g release because this might have led to a greater beneﬁcial
effect. Charoensup et al. found that this approach with ceftazidime
delivered a modicum of success, and the present in-depth
immunological analysis and measurements of the bacterial burden
compliments, supports, and explains why anti-HMGB1 treatment
was beneﬁcial.
An important consideration is the type of antibiotic used.
Charoensup et al. used ceftazidime in conjunction with anti-
HMGB1 and demonstrated a positive effect associated with
combining these drugs.23 The data are not reported here, but we
also performed experiments combining anti-HMGB1 therapy with
the antibiotic doxycycline at sub-optimal concentrations (data not
shown). No survival beneﬁt for the combination was observed;
however this may indicate that serious consideration should be
given to the antibiotic that should be taken, as many antibiotics
have direct effects on the immune system.
Anti-HMGB1 therapy is just one of several promising therapies
reported in the literature. CpGs are DNA motifs that can instigateimmune activity via toll-like receptors and these have been shown
to be useful in generating a helpful immune response against B.
pseudomallei.37–43 Additionally, outer membrane vesicles are also
potent instigators of inﬂammation and these have been shown to
be effective against B. pseudomallei infection.44 In a similar way to
anti-HMGB1 treatment, the immune response can also be directed
to the beneﬁt of the host during infection by B. pseudomallei, by the
introduction of signals and inhibitors such as IL-1 inhibitors,20 the
addition of endogenous IL-18,14 the inhibition of COX-2 signal-
ling,36 or the direct application of IFN-g.15,45 The present work, and
the work described above that targets the immune system, may
provide future treatment options, although substantial issues
exist. It is very difﬁcult to prioritize treatment options based on the
scale of therapeutic effect, as much of this work has been
performed using different infection models. Future work should
be attempted to compare treatments using the same model/s.
Additionally, therapeutic options should be ranked on the
availability of clinical drugs and the likely side effects. Also, the
possibility exists that these different therapeutics might be used in
combination. For example, CpGs might be used where exposure
seems certain; antibiotic would be used to reduce bacterial load,
while anti-IL1 helps generate a more appropriate immune
response. This immune response, which is balanced more towards
IFN-g signalling, might be further bolstered by the addition of
further IFN-g, and some of the unnecessary damage-associated
inﬂammation might be tempered with anti-HMGB1. In combina-
tion, these therapies would increase the likelihood of a positive
outcome.
In conclusion, the release of the DAMP HMGB1 was observed
and it is hypothesized that this may present a therapeutic target.
Following further evaluation, it is concluded that an experimental
reduction in HMGB1 signalling is beneﬁcial during melioidosis and
is likely driven by a reduction of unnecessary inﬂammation.
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